Regulatory7 May 2026, 10:41 pm
Shukra Pharma: No Deviation in Preferential Issue Funds
AI Summary
Shukra Pharmaceuticals Ltd. reports no deviation or variation in the utilization of proceeds from its preferential issue of convertible warrants, as per Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The funds raised, amounting to ₹3,94,65,500, are being utilized as per the objects mentioned in the Extra Ordinary General Meeting notice dated November 1, 2025. The audit committee has reviewed and confirmed the absence of any deviation.
Key Highlights
- Shukra Pharma confirms no deviation in use of preferential issue proceeds.
- Funds utilized as per EGM notice dated November 1, 2025.
- ₹3,94,65,500 raised from convertible warrants issue.
- Audit Committee reviewed and approved the statement of no deviation.
- Report filed for quarter and year ended March 31, 2026.
Price Impact
More from SHUKRAPHAR